Biointron

Biointron, founded in 2012, operates as a specialized service provider within the biotechnology sector, focusing on high-throughput recombinant antibody and protein expression. The company utilizes an integrated platform to deliver comprehensive discovery services, including antibody humanization, hybridoma sequencing, and domain antibody development. By streamlining the transition from gene sequence to purified antibodies, Biointron supports global pharmaceutical and biotech research initiatives with high-tech biological reagents and custom service solutions.

The organization maintains a robust operational footprint with 3 locations, facilitating rapid service delivery for complex biological projects. Biointron currently employs 500-1,000 employees who manage high-volume workflows, ensuring that clients receive purified antibodies within a 2-week turnaround time. This operational efficiency is central to their business model, allowing them to serve over 1,500 biotech and pharmaceutical companies worldwide. Their technical infrastructure is designed to handle large-scale discovery requirements while maintaining strict quality standards for every sample produced.

As a key player in the B2B life sciences market, Biointron continues to expand its influence across Asia and the global research community, reporting annual revenue of $102.8M. The company’s commitment to technical excellence is driven by its specialized workforce. Meet Biointron's team to learn about the leadership and technical experts behind their integrated discovery platform. By focusing on rapid, high-throughput sequencing and expression, Biointron remains a critical partner for organizations seeking to accelerate their drug discovery pipelines and optimize their research outcomes through reliable, custom-engineered biological solutions.